Australia's most trusted
source of pharma news
Friday, 19 April 2024
Posted 26 October 2021 PM
In a neck-and-neck finish, both Pfizer's Comirnaty and AstraZeneca's Vaxzevria have emerged as at least 90 per cent effective in preventing deaths from the Delta COVID-19 variant, according to a new study from Scotland.
Results recently published as a letter in The New England Journal of Medicine, reveal overall vaccine effectiveness in double vaccinated people who had tested positive for COVID-19 is 90 per cent for Comirnaty and 91 per cent for Vaxzevria.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.